دورية أكاديمية
Novel chimeric thyroid-stimulating hormone-receptor bioassay for thyroid-stimulating immunoglobulins.
| العنوان: | Novel chimeric thyroid-stimulating hormone-receptor bioassay for thyroid-stimulating immunoglobulins. |
|---|---|
| المؤلفون: | Lytton SD; Department of Medicine I, Gutenberg University Medical Center, Mainz, Germany., Li Y, Olivo PD, Kohn LD, Kahaly GJ |
| المصدر: | Clinical and experimental immunology [Clin Exp Immunol] 2010 Dec; Vol. 162 (3), pp. 438-46. |
| نوع المنشور: | Comparative Study; Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Oxford University Press Country of Publication: England NLM ID: 0057202 Publication Model: Print Cited Medium: Internet ISSN: 1365-2249 (Electronic) Linking ISSN: 00099104 NLM ISO Abbreviation: Clin Exp Immunol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2022- : Oxford : Oxford University Press Original Publication: Oxford : Blackwell Scientific Publications |
| مواضيع طبية MeSH: | Graves Disease/*diagnosis , Receptors, Thyrotropin/*metabolism , Recombinant Fusion Proteins/*metabolism, Animals ; Biological Assay ; CHO Cells ; Cricetinae ; Cricetulus ; Graves Disease/blood ; Graves Disease/immunology ; Graves Disease/physiopathology ; Humans ; Immunoglobulins, Thyroid-Stimulating/blood ; Protein Binding/genetics ; Protein Engineering ; Receptors, Thyrotropin/genetics ; Recombinant Fusion Proteins/genetics ; Reproducibility of Results ; Sensitivity and Specificity ; Transgenes/genetics |
| مستخلص: | Thyroid-stimulating immunoglobulins (TSI) are a functional biomarker of Graves' disease (GD). To develop a novel TSI bioassay, a cell line (MC4-CHO-Luc) was bio-engineered to constitutively express a chimeric TSH receptor (TSHR) and constructed with a cyclic adenosine monophosphate (cAMP)-dependent luciferase reporter gene that enables TSI quantification. Data presented as percentage of specimen-to-reference ratio (SRR%) were obtained from 271 patients with various autoimmune and thyroid diseases and 180 controls. Sensitivity of 96% and specificity of 99% for untreated GD were attained by receiver operating characteristic analysis, area under the curve 0·989, 95% confidence interval 0·969-0·999, P = 0·0001. Precision testing of manufactured reagents of high, medium, low and negative SRR% gave a percentage of coefficient-of-variation of 11·5%, 12·8%, 14·5% and 15·7%, respectively. There was no observed interference by haemoglobin, lipids and bilirubin and no non-specific stimulation by various hormones at and above physiological concentrations. TSI levels from GD patients without (SRR% 406 ± 134, mean ± standard deviation) or under anti-thyroid treatment (173 ± 147) were higher (P < 0·0001) compared with TSI levels of patients with Hashimoto's thyroiditis (51 ± 37), autoimmune diseases without GD (24 ± 10), thyroid nodules (30 ± 26) and controls (35 ± 18). The bioassay showed greater sensitivity when compared with anti-TSHR binding assays. In conclusion, the TSI-Mc4 bioassay measures the functional biomarker accurately in GD with a standardized protocol and could improve substantially the diagnosis of autoimmune diseases involving TSHR autoantibodies. (© 2010 The Authors. Clinical and Experimental Immunology © 2010 British Society for Immunology.) |
| References: | J Clin Endocrinol Metab. 1983 Oct;57(4):782-91. (PMID: 6136523) Endocrinology. 1958 Sep;63(3):372-82. (PMID: 13574093) J Clin Endocrinol Metab. 2010 May;95(5):2123-31. (PMID: 20237164) Thyroid. 1997 Dec;7(6):867-77. (PMID: 9459630) J Immunol Methods. 1988 Jun 28;111(1):117-23. (PMID: 2455750) Clin Endocrinol (Oxf). 1994 May;40(5):645-52. (PMID: 7912172) Endocrinology. 1969 Sep;85(3):592-3. (PMID: 5793040) J Clin Endocrinol Metab. 1993 Feb;76(2):499-503. (PMID: 8094393) Endocr Rev. 1998 Dec;19(6):673-716. (PMID: 9861544) J Clin Endocrinol Metab. 1998 Jul;83(7):2302-8. (PMID: 9661599) Autoimmunity. 2008 Sep;41(6):419-28. (PMID: 18781467) Clin Chem. 1988 Feb;34(2):244-9. (PMID: 2893670) J Clin Endocrinol Metab. 2009 Dec;94(12):4742-8. (PMID: 19850692) Clin Biochem Rev. 2008 Aug;29 Suppl 1:S49-52. (PMID: 18852857) Clin Endocrinol (Oxf). 2009 Oct;71(4):566-73. (PMID: 19170704) Clin Endocrinol (Oxf). 2001 Mar;54(3):355-64. (PMID: 11298088) Thyroid. 2000 Sep;10(9):809-13. (PMID: 11041459) J Clin Endocrinol Metab. 2004 Oct;89(10):5076-80. (PMID: 15472208) Autoimmunity. 2003 Sep-Nov;36(6-7):331-7. (PMID: 14669940) Horm Metab Res. 2005 Dec;37(12):741-4. (PMID: 16372227) Clin Endocrinol (Oxf). 1999 Mar;50(3):365-72. (PMID: 10435063) J Autoimmun. 2009 May-Jun;32(3-4):231-9. (PMID: 19307103) J Clin Endocrinol Metab. 2010 Jan;95(1):62-5. (PMID: 20056811) J Autoimmun. 2007 Dec;29(4):246-9. (PMID: 17888625) Clin Chem. 2009 Jan;55(1):183-6. (PMID: 19028818) Clin Chim Acta. 2009 Mar;401(1-2):84-9. (PMID: 19091299) Clin Endocrinol (Oxf). 1998 Nov;49(5):577-81. (PMID: 10197071) |
| المشرفين على المادة: | 0 (Immunoglobulins, Thyroid-Stimulating) 0 (Receptors, Thyrotropin) 0 (Recombinant Fusion Proteins) |
| تواريخ الأحداث: | Date Created: 20101113 Date Completed: 20110308 Latest Revision: 20211020 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC3026547 |
| DOI: | 10.1111/j.1365-2249.2010.04266.x |
| PMID: | 21070207 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1365-2249 |
|---|---|
| DOI: | 10.1111/j.1365-2249.2010.04266.x |